Techno Medica (6678) Q3 2026 earnings summary

Executive summary

• Revenue for the nine months ended December 31, 2025, increased by 12.3% year-over-year to ¥7,238 million, driven by strong sales of blood collection tube preparation systems in both domestic and overseas markets.

• Operating profit rose 41.9% year-over-year to ¥829 million, and ordinary profit increased 46.2% to ¥861 million, reflecting higher sales and reduced SG&A expenses, particularly lower R&D costs.

• Net profit grew 7.9% year-over-year to ¥460 million, despite recording a special loss related to discontinuation of certain product models.

Financial highlights

• Gross profit was ¥3,415 million, up 5.3% year-over-year, with a gross margin of approximately 47.2%.

• SG&A expenses decreased by 2.8% year-over-year to ¥2,586 million.

• EPS for the period was ¥66.44, compared to ¥61.66 in the prior year.

• Total assets at quarter-end were ¥16,953 million, down ¥985 million from the previous fiscal year-end.

• Net assets increased to ¥14,474 million, with an equity ratio of 85.4%, up 5.2 points year-over-year.

Outlook and guidance

• Full-year revenue forecast remains unchanged at ¥10,600 million, with operating profit projected at ¥1,480 million and net profit at ¥1,100 million.

• Full-year EPS is forecast at ¥158.86.

• No revision to previously announced guidance.